NCODA and Florida Cancer Specialists & Research Institute jointly announced the development of a novel oncology stakeholder education exchange program.
Cazenovia, NY, August 16, 2022 – Florida Cancer Specialists & Research Institute (FCS) jointly announced with NCODA the development of a virtual learning platform that offers focused education for governance-level Board members, disease-state experts, and generalists.
FCS will be the first to utilize this new program, with the latest updates and detailed information to be made available in real-time at the user’s convenience on NCODA’s platform, Rxchange.
Lucio Gordan, MD, FCS chief medical officer for Therapeutics and Analytics, said, “organizing the education and information exchange between providers and other health care stakeholders has been long overdue. Rxchange will greatly enhance the 2-way flow of information in an environment of rapid and unprecedented developments in cancer care and help to enhance overall patient care.“
Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma
October 27th 2023Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More